VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
For more details, the full press release is available at https://ibn.fm/1je4A. The company's newsroom can be accessed at http://ibn.fm/VRXA for the latest updates on VRXA.
The BiTAC platforms represent a significant advancement in cancer therapy, potentially offering more precise treatment options with reduced side effects. By leveraging tumor-restricted activation, BiTAC-ADC aims to deliver therapeutic agents directly to cancer cells, sparing healthy tissue. Similarly, BiTAC-TCE engages T cells to target and destroy tumor cells, with data suggesting broad applicability across solid tumors.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's focus on quality-by-design principles and transformative technologies positions it as a potential leader in next-generation antibody-based therapeutics.
The BIO International Convention serves as a key platform for VERAXA to engage with potential partners, showcasing its platforms to a global audience of biotech and pharmaceutical stakeholders. The data presented at AACR and the recent proof-of-concept results are expected to generate significant interest, potentially leading to collaborative development agreements.
As the company continues to advance its pipeline, the partnering discussions at BIO could be pivotal in accelerating the clinical development and commercialization of these innovative cancer therapies.
